Mechanisms and consequences of fibrosis in systemic sclerosis (original) (raw)
Denton CP and Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol18: 271–290 ArticleCAS Google Scholar
Merkel PA et al. (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum46: 2410–2420 Article Google Scholar
Apras S et al. (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum48: 2256–2261 ArticleCAS Google Scholar
Pope JE et al. (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum44: 1351–1358 ArticleCAS Google Scholar
Takehara K (2003) Hypothesis. Pathogenesis of systemic sclerosis. J Rheumatol30: 755–759 PubMed Google Scholar
Flavahan NA et al. (2003) The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am29: 275–291 Article Google Scholar
Lunardi C et al. (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med6: 1183–1186 ArticleCAS Google Scholar
Worda M et al. (2003) In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum48: 2605–2614 ArticleCAS Google Scholar
Distler O et al. (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res95: 109–116 ArticleCAS Google Scholar
Del Papa N et al. (2004) Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum50: 1296–1304 Article Google Scholar
Liu X et al. (2005) Paclitaxel modulates TGFβ signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med2: e354 Article Google Scholar
Kuwana M et al. (2003) HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol30: 2392–2397 CASPubMed Google Scholar
Sato H et al. (2004) The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum50: 558–564 ArticleCAS Google Scholar
Henault J et al. (2004) Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum50: 3265–3274 ArticleCAS Google Scholar
Ahmed SS and Tan FK (2003) Identification of novel targets in scleroderma: update on population studies, cDNA arrays, SNP analysis, and mutations. Curr Opin Rheumatol15: 766–771 ArticleCAS Google Scholar
Sato S et al. (2001) Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford)40: 1135–1140 ArticleCAS Google Scholar
Carvalho D et al. (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest97: 111–119 ArticleCAS Google Scholar
Sato S et al. (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol41: 1123–1133 ArticleCAS Google Scholar
Bouros D et al. (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med165: 1581–1586 Article Google Scholar
Sappino AP et al. (1990) Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol137: 585–591 CASPubMedPubMed Central Google Scholar
Mimura Y et al. (2005) Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol124: 886–892 ArticleCAS Google Scholar
Laplante P et al. (2005) Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol174: 5740–5749 ArticleCAS Google Scholar
Postlethwaite AE et al. (2004) Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol16: 733–738 Article Google Scholar
Rajkumar V et al. (2005) Shared expression of phenotypic markers indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res7: R1113–R1123 ArticleCAS Google Scholar
Denton CP and Abraham DJ (2001) Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol13: 505–511 ArticleCAS Google Scholar
Leask A et al. (2002) Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep4: 136–142 Article Google Scholar
Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum48: 1190–1199 ArticleCAS Google Scholar
Ong VH et al. (2003) Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum48: 1979–1991 ArticleCAS Google Scholar
Kawaguchi Y et al. (2003) Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1α in systemic sclerosis. Arthritis Rheum48: 193–202 ArticleCAS Google Scholar
Asano Y et al. (2004) Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest113: 253–264 ArticleCAS Google Scholar
Mori Y et al. (2003) Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum48: 1964–1978 ArticleCAS Google Scholar
Clements PJ et al. (2004) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum33: 249–263 ArticleCAS Google Scholar
Seibold JR (2001) Clinical trials: types, design, and end-points. Curr Opin Rheumatol13: 512–515 ArticleCAS Google Scholar
Carbone LD et al. (2004) Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum50: 2713–2715 ArticleCAS Google Scholar
Denton CP et al. (2004) Anti-TGFβ1 therapy for diffuse cutaneous systemic sclerosis: a multicenter, randomized, placebo-controlled Phase I/II trial of CAT-192 [abstract #1851]. Arthritis Rheum50 (Suppl 9): S691 Google Scholar
Tyndall A and Matucci-Cerinic M (2003) Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther3: 1041–1049 Article Google Scholar
Desai SR et al. (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology232: 560–567 Article Google Scholar
Airo P et al. (2004) Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol22: 573–578 CASPubMed Google Scholar
Tashkin DP (2005) Major outcomes of SLS [abstract #B27]. American Thoracic Society International Conference, San Diego, May 2005
Highland KB and Silver RM (2005) Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study. Curr Rheumatol Rep7: 135–141 Article Google Scholar
Khanna D et al. (2005) Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum52: 592–600 Article Google Scholar
Mukerjee D et al. (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis62: 1088–1093 ArticleCAS Google Scholar
Steen V and Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum48: 516–522 Article Google Scholar
Yap LB et al. (2004) The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem37: 847–856 ArticleCAS Google Scholar
Allanore Y et al. (2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum48: 3503–3508 ArticleCAS Google Scholar
Farber HW and Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med351: 1655–1665 ArticleCAS Google Scholar
Hachulla E and Coghlan JG (2004) A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis63: 1009–1014 ArticleCAS Google Scholar
Denton CP et al. (2005) Bosentan therapy for pulmonary arterial hypertension related to systemic sclerosis [abstract]. Ann Rheum Dis64 (Suppl 3): 294 Google Scholar
Steen VD et al. (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med113: 352–357 ArticleCAS Google Scholar
Denton CP et al. (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol33: 90–92 ArticleCAS Google Scholar
Steen VD and Medsger TA Jr (1998) Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum41: 1613–1619 ArticleCAS Google Scholar
DeMarco PJ et al. (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum46: 2983–2989 ArticleCAS Google Scholar
Saccardi R et al. (2004) Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant34: 877–881 ArticleCAS Google Scholar
Jaovisidha K et al. (2005) Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum34: 689–702 Article Google Scholar
Kenefick NJ et al. (2002) Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut51: 881–883 ArticleCAS Google Scholar
Calamia KT et al. (2000) Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis. Clin Exp Rheumatol18: 605–608 CASPubMed Google Scholar
Yusoff I et al. (2002) Argon plasma coagulation for treatment of watermelon stomach. Endoscopy34: 407–410 ArticleCAS Google Scholar